|
MechanismAT III activators |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date19 May 1944 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date25 Sep 2024 |
100 Clinical Results associated with Fresenius Kabi USA, Inc.
0 Patents (Medical) associated with Fresenius Kabi USA, Inc.
100 Deals associated with Fresenius Kabi USA, Inc.
100 Translational Medicine associated with Fresenius Kabi USA, Inc.